MIRA
INFORM REPORT
|
Report Date : |
26.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
HUNAN YUXIN PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
Longxutang, Shuangqing District, Shaoyang, Hunan Province,
422000 PR |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
26.03.2002 |
|
|
|
|
Com. Reg. No.: |
430500000005686 |
|
|
|
|
Legal Form : |
Limited Liabilities Company |
|
|
|
|
Line of Business : |
Manufacturing and selling pharmaceutical products. |
|
|
|
|
No. of Employees : |
288 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed, centrally planned system to a more market-oriented one that plays a major global role - in 2010 China became the world's largest exporter. Reforms began with the phasing out of collectivized agriculture, and expanded to include the gradual liberalization of prices, fiscal decentralization, increased autonomy for state enterprises, creation of a diversified banking system, development of stock markets, rapid growth of the private sector, and opening to foreign trade and investment. China has implemented reforms in a gradualist fashion. In recent years, China has renewed its support for state-owned enterprises in sectors it considers important to "economic security," explicitly looking to foster globally competitive national champions. After keeping its currency tightly linked to the US dollar for years, in July 2005 China revalued its currency by 2.1% against the US dollar and moved to an exchange rate system that references a basket of currencies. From mid 2005 to late 2008 cumulative appreciation of the renminbi against the US dollar was more than 20%, but the exchange rate remained virtually pegged to the dollar from the onset of the global financial crisis until June 2010, when Beijing allowed resumption of a gradual appreciation. The restructuring of the economy and resulting efficiency gains have contributed to a more than tenfold increase in GDP since 1978. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, China in 2012 stood as the second-largest economy in the world after the US, having surpassed Japan in 2001. The dollar values of China's agricultural and industrial output each exceed those of the US; China is second to the US in the value of services it produces. Still, per capita income is below the world average. The Chinese government faces numerous economic challenges, including: (a) reducing its high domestic savings rate and correspondingly low domestic demand; (b) sustaining adequate job growth for tens of millions of migrants and new entrants to the work force; (c) reducing corruption and other economic crimes; and (d) containing environmental damage and social strife related to the economy's rapid transformation. Economic development has progressed further in coastal provinces than in the interior, and by 2011 more than 250 million migrant workers and their dependents had relocated to urban areas to find work. One consequence of population control policy is that China is now one of the most rapidly aging countries in the world. Deterioration in the environment - notably air pollution, soil erosion, and the steady fall of the water table, especially in the North - is another long-term problem. China continues to lose arable land because of erosion and economic development. The Chinese government is seeking to add energy production capacity from sources other than coal and oil, focusing on nuclear and alternative energy development. In 2010-11, China faced high inflation resulting largely from its credit-fueled stimulus program. Some tightening measures appear to have controlled inflation, but GDP growth consequently slowed to under 8% for 2012. An economic slowdown in Europe contributed to China's, and is expected to further drag Chinese growth in 2013. Debt overhang from the stimulus program, particularly among local governments, and a property price bubble challenge policy makers currently. The government's 12th Five-Year Plan, adopted in March 2011, emphasizes continued economic reforms and the need to increase domestic consumption in order to make the economy less dependent on exports in the future. However, China has made only marginal progress toward these rebalancing goals.
Source
: CIA
Company name and address
HUNAN YUXIN PHARMACEUTICAL
CO., LTD.
Longxutang, shuangqing district, shaoyang,
hunan province, 422000 PR CHINA
TEL: 86 (0) 739-5271168
FAX: 86 (0) 739-5271610
EXECUTIVE SUMMARY
INCORPORATION DATE : MAR. 26, 2002
REGISTRATION NO. : 430500000005686
REGISTERED LEGAL FORM : Limited liabilities co.
STAFF STRENGTH :
288
REGISTERED CAPITAL : CNY 21,400,000
BUSINESS LINE :
manufacturing & Trading
TURNOVER :
CNY 216,370,000 (AS OF DEC. 31,
2012)
EQUITIES : CNY 102,850,000
(AS OF DEC. 31, 2012)
PAYMENT :
AVERAGE
MARKET CONDITION : COMPETITIVE
FINANCIAL CONDITION : fairly STABLE
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.13 = USD 1
Adopted abbreviations:
ANS - amount not
stated
NS - not stated
SC - subject company
(the company inquired by you)
NA - not available
CNY - China Yuan
Renminbi
SC was registered as a limited liabilities co. at local
Administration for Industry & Commerce (AIC - The official body of issuing
and renewing business license) on Mar. 26, 2002.
Company Status: Limited Liabilities Co. This form of business in PR
China is defined as a legal person. No more than fifty shareholders contribute
its registered capital jointly. Shareholders bear limited liability to the
extent of shareholding, and the co. is liable for its debts only to extent
of its total assets. The characteristics of this form of co. are as
follows: Upon the establishment of the
co., an investment certificate is issued to the each of shareholders. The board of directors is
comprised of three to thirteen members. The minimum registered capital
for a co. is CNY 30,000. Shareholders may take their
capital contributions in cash or by means of tangible assets or intangible
assets such as industrial property and non-patented technology. Cash contributed by all
shareholders must account for at least 30% of the registered capital. Existing shareholders have
pre-exemption right to purchase shares of the co. offered for sale by the
other shareholders and to subscribe for the newly increased registered
capital of the co.
SC’s registered
business scope includes chemicals [excluding the hazard chemicals, precursor chemicals,
state monitored chemicals], bulk pharmaceutical chemicals and pharmaceutical
chemical raw material; import and export of various goods and technologies,
excluding the goods forbidden by the government; technology researching,
consulting and transfer.
SC is mainly
engaged in manufacturing and selling pharmaceutical products.
Mr. Shen
Yuliang has been legal representative,
chairman and general manager of SC since 2002.
SC is known to
have approx. 288 employees at present.
SC
is currently operating at the above stated address, and this address houses its
operating office and factory in the industrial zone of Shaoyang. Our checks
reveal that SC owns the total premise about 10,000 square meters.
http://www.steroidchem.com/ The design is professional and the content is
well organized. At present the web site is in both English and Chinese
versions.
E-Mail: info@steroidchem.com
Changes
of its registered information are as follows:
|
Date of change |
Item |
Before the change |
After the change |
|
|
Registered
capital |
CNY 1,660,000 |
CNY 10,000,000 |
|
Shareholders (Shareholding) |
Shen Yuliang 78.01% He Huixian 21.99% |
Shen Yuliang 30.34% He Huixian 10.02% Hu Aiguo 15.04% Liu Xirong 12.02% Gan Hongxing 13.04% Xie Laibin 10.02% Xie Wenwu 9.52% |
|
|
|
Company name |
Shaoyang Steroidchem Pharmaceutical Co.,
Ltd. |
Hunan Steroidchem Pharmaceutical Co., Ltd. |
|
|
Registration No. |
4305002800530 |
The present one |
|
|
Shareholders (Shareholding) |
Shen Yuliang 30.34% He Huixian 10.02% Hu Aiguo 15.04% Liu Xirong 12.02% Gan Hongxing 13.04% Xie Laibin 10.02% Xie Wenwu 9.52% |
Shen Yuliang 40.36% Hu Aiguo 15.04% Liu Xirong 12.02% Gan Hongxing 13.04% Xie Laibin 10.02% Xie Wenwu 9.52% |
|
|
Shareholders (Shareholding) |
Shen Yuliang 40.36% Hu Aiguo 15.04% Liu Xirong 12.02% Gan Hongxing 13.04% Xie Laibin 10.02% Xie Wenwu 9.52% |
Shen Yuliang 40.36% Hu Aiguo 15.04% Liu Xirong 21.54% Gan Hongxing 13.04% Xie Laibin 10.02% |
|
|
Company name |
Hunan Steroidchem Pharmaceutical Co., Ltd. |
The present one |
|
Registered
capital |
CNY 10,000,000 |
CNY 16,000,000 |
|
|
|
Registered
capital |
CNY 16,000,000 |
The present amount |
|
Shareholders (Shareholding) |
Shen Yuliang 40.36% Hu Aiguo 15.04% Liu Xirong 21.54% Gan Hongxing 13.04% Xie Laibin 10.02% |
Xiangjiang Industry Investment Co., Ltd. 20.23% Shen Yuliang 30.18% Hu Aiguo 11.25% Liu Xirong 16.10% Gan Hongxing 9.75% Xie Laibin 7.49% Li Shuilong 2% Cao Chunyu 0.4% Fu Jie 0.4% Li Jianguo 0.4% Jiang Qingfeng 0.4% Shu Zhijian 0.4% Shen Yujun 1% |
|
|
|
Shareholders (Shareholding) |
Xiangjiang Industry Investment Co., Ltd. 20.23% Shen Yuliang 30.18% Hu Aiguo 11.25% Liu Xirong 16.10% Gan Hongxing 9.75% Xie Laibin 7.49% Li Shuilong 2% Cao Chunyu 0.4% Fu Jie 0.4% Li Jianguo 0.4% Jiang Qingfeng 0.4% Shu Zhijian 0.4% Shen Yujun 1% |
Xiangjiang Industry Investment Co., Ltd. 20.23% Shen Yuliang 35.18% Hu Aiguo 11.25% Liu Xirong 11.10% Gan Hongxing 9.75% Xie Laibin 7.49% Li Shuilong 2% Cao Chunyu 0.4% Fu Jie 0.4% Li Jianguo 0.4% Jiang Qingfeng 0.4% Shu Zhijian 0.4% Shen Yujun 1% |
|
|
Shareholders (Shareholding) |
Xiangjiang Industry Investment Co., Ltd. 20.23% Shen Yuliang 35.18% Hu Aiguo 11.25% Liu Xirong 11.10% Gan Hongxing 9.75% Xie Laibin 7.49% Li Shuilong 2% Cao Chunyu 0.4% Fu Jie 0.4% Li Jianguo 0.4% Jiang Qingfeng 0.4% Shu Zhijian 0.4% Shen Yujun 1% |
Xiangjiang Industry Investment Co., Ltd. 20.23% Shen Yuliang 46.28% Hu Aiguo 11.25% Gan Hongxing9.75% Xie Laibin 7.49% Li Shuilong 2% Cao Chunyu 0.4% Fu Jie0.4% Li Jianguo 0.4% Jiang Qingfeng 0.4% Shu Zhijian 0.4% Shen Yujun 1% |
|
Unknown |
Shareholders |
Xiangjiang Industry Investment Co., Ltd. 20.23% Shen Yuliang 46.28% Hu Aiguo 11.25% Gan Hongxing 9.75% Xie Laibin 7.49% Li Shuilong 2% Cao Chunyu 0.4% Fu Jie 0.4% Li Jianguo 0.4% Jiang Qingfeng 0.4% Shu Zhijian 0.4% Shen Yujun 1% |
Present ones |
For the past two years there is no record of litigation.
MAIN SHAREHOLDERS:
Name %
of Shareholding
Li Shuilong 2.0
Xiangjiang Industry Investment Co., Ltd. 20.23
Shen Yujun 1.0
Shen Yuliang 75.97
Shu Zhijian 0.4
Xiangjiang Industry Investment Co., Ltd.
=============================
Registration no.: 430000000061012
Legal representative: Cheng Xin
Registered capital: CNY 2,000,000,000
Legal form: Limited Liabilities Co.
Date of incorporation: June 30, 2009
l
Legal representative, Chairman and General manager:
Mr. Shen Yuliang , born in 1963, with
university education. He is currently responsible for the overall management of
SC.
Working Experience(s):
From 2002 to present Working
in SC as legal representative, chairman and general manager;
Also working in Changsha
Dekai Pharmaceutical Chemical Co., Ltd. as legal representative
SC is mainly
engaged in manufacturing and selling pharmaceutical products. (该公司目前实际主要从事生产销售医药产品。)
SC’s products
mainly include:
8DM, B11 acetate, DB11,
Diflorasone, Dutasteride, Estradiol,
Estrone, Estriolm, Ethisterone, Ethinylestradiol, Exemestane , Finasteride,
Flumethasone, Fluticasone propionate, Fluorometholone Acetate, Fluorogesterone
Acetate, Fluocinolone acetonide, Halobetasol Propionate, Hydrocortisone
acetate, Hydrocortisone Hemisuccinate, Hydrocortisone butyrate,
Medroxyprogesterone Acetate, Megestrol Acetate, Meprednisone, Nomegestrol
Acetate, Prednisolone Acetate 1, Prednisolone Sodium Phosphate, Triamcinolone
Acetonide, Triamcinolone diacetate, etc.
SC sources its materials 100% from domestic
market. SC sells 10% of its products in domestic market, and 90% to overseas
market.
The buying terms of SC include Check, T/T and Credit of 30-60 days. The
payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
Note: SC’s management refused to release
information about its customers and suppliers.
Sales Department:
=============
Add: Room 2506 & 2507, 28/F, Xingwei Mingzuo Bldg., No. 460,
Shaoshan Rd. (N), Changsha, Hunan province
Tel: 86(0)731-82762868/82762898
Fax: 86(0)731-85551702
Subsidiary:
=========
Changsha
Dekai Pharmaceutical Chemical Co., Ltd.
Incorporation Date: Jun. 4, 2007
Registration No.: 430111000028106
Registered Legal Form: One-Person
Limited Liability Company
Chief Executive : Mr. Shen Yuliang
Registered
Capital: CNY 1,010,000
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent
payment record: None in our database.
Debt collection record: No overdue amount owed by SC was placed to us for
collection within the last 6 years.
SC’s accountant
refused to release the bank details.
Balance Sheet
Unit: CNY’000
|
|
As
of Dec. 31, 2012 |
|
Cash & bank |
31,930 |
|
Inventory |
98,120 |
|
Accounts
receivable |
45,890 |
|
Other
receivables |
83,960 |
|
Other current
assets |
5,900 |
|
|
------------------ |
|
Current assets |
265,800 |
|
Fixed assets net
value |
27,860 |
|
Long term
investment |
2,000 |
|
Projects under
construction |
0 |
|
Intangible and
other assets |
16,900 |
|
|
------------------ |
|
Total assets |
312,560 |
|
|
=========== |
|
Short loan |
149,750 |
|
Accounts payable |
-3,340 |
|
Bills payable |
60,020 |
|
Advances from
clients |
0 |
|
Taxes payable |
450 |
|
Other Accounts
payable |
760 |
|
Other current
liabilities |
0 |
|
|
------------------ |
|
Current
liabilities |
207,640 |
|
Long term
liabilities |
2,070 |
|
|
------------------ |
|
Total
liabilities |
209,710 |
|
Equities |
102,850 |
|
|
------------------ |
|
Total
liabilities & equities |
312,560 |
|
|
=========== |
Income Statement
Unit: CNY’000
|
|
As of Dec. 31,
2012 |
|
Turnover |
216,370 |
|
Cost of goods sold |
178,000 |
|
Sales expense |
/ |
|
Management expense |
/ |
|
Finance expense |
/ |
|
Profit before tax |
10,750 |
|
Less: profit tax |
1,620 |
|
Profits |
9,130 |
Note: We didn’t find SC’s detailed income statement.
Important
Ratios
=============
|
|
As of Dec. 31, 2012 |
|
*Current ratio |
1.28 |
|
*Quick ratio |
0.81 |
|
*Liabilities
to assets |
0.67 |
|
*Net profit
margin (%) |
4.22 |
|
*Return on
total assets (%) |
2.92 |
|
*Inventory
/Turnover ×365 |
166 days |
|
*Accounts
receivable/Turnover ×365 |
78 days |
|
*Turnover/Total
assets |
0.69 |
|
* Cost of
goods sold/Turnover |
0.82 |
PROFITABILITY:
AVERAGE
l
The turnover of SC appears fairly good.
l
SC’s net profit margin is average.
l
SC’s return on total assets is average.
l
SC’s cost of goods sold is average, comparing with
its turnover.
LIQUIDITY: AVERAGE
l
The current ratio of SC is maintained in a normal
level.
l
SC’s quick ratio is maintained in a normal level.
l
The inventory of SC appears fairly large.
l
The accounts receivable of SC appears average.
l
The short-term loan of SC appears large.
l
SC’s turnover is in a fair level, comparing with
the size of its total assets.
LEVERAGE: AVERAGE
l
The debt ratio of SC is average.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Fairly stable.
SC is considered medium-sized in its line with fairly stable financial
conditions. The large amount of inventory and short term loans could be a threat
to SC’s financial conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.64.69 |
|
UK Pound |
1 |
Rs.100.80 |
|
Euro |
1 |
Rs.96.30 |
INFORMATION DETAILS
|
Report Prepared
by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.